NDAORALTABLET
Approved
May 2006
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
9
Data completeness
5/8 — Partial
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Azilect (rasagiline mesylate) is a selective monoamine oxidase-B (MAO-B) inhibitor indicated for Parkinson's disease as monotherapy or adjunct to levodopa. It works by inhibiting the breakdown of dopamine in the brain, helping to maintain dopamine levels and slow disease progression.
$0.002BPart D
LOE ApproachingDeclining
11mo to LOEWith LOE approaching in 0.9 years and competitive pressure at 25%, the brand team is entering a managed decline phase with reduced headcount and focus shifting toward generic transition support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Azilect® In Wearing-Off (AIWO)
Started Jan 2014
261 enrolled
Parkinson's Disease
Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
Started Dec 2011
321 enrolled
Parkinson's Disease
Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
Started Jan 2011
132 enrolled
Parkinson's Disease
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Started Mar 2010
121 enrolled
Depressive SymptomsParkinson's Disease
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
Started Jan 2010
44 enrolled
Progressive Supranuclear Palsy
Worked on AZILECT at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.